Drug Trial Radar · NCT07885462
Coronary MicrovAscular Diseases Intervention With Compound Danshen Dropping Pills
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
496
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Nov 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Qilu Hospital of Shandong UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Objective: To investigate the effect of Compound Danshen Dripping Pills (CDDP)on improving coronary flow reserve(CFR) in patients with coronary microvascular disease (CMVD) and to evaluate their efficacy and safety. Study Design: Randomized, double-blind, placebo-controlled, multicenter clinical trial. Study population: Patients with ischemia-related CMVD and myocardial infarction-related CMVD. Intervention:Treatment group:standard therapy plus CDDP, Twenty pills (27 mg each) orally, three times daily after meals.Control group:standard therapy plus matching placebo, Twenty pills (27 mg each) orally, three times daily after meals.Treatment duration 12 months. Primary Endpoint: Change in CFRmax from baseline to Month 12 (ΔCFRmax-12m) by Transthoracic Doppler echocardiography(TTE).
Conditions
- Coronary Microvascular Disease
Interventions
Compound Danshen Dripping PillsDrug
20 pills (540 mg) orally three times daily for 12 months. Each pill weighs 27 mg, containing Radix Salviae miltiorrhizae, Radix Notoginseng, and Borneolum Syntheticum. Manufactured and supplied by Tasly Pharmaceutical Group Co., Ltd.
PlaceboDrug
Placebo pills identical to Compound Danshen Dripping Pills in appearance, taste, and packaging, 20 pills orally three times daily for 12 months.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in peak coronary flow reserve (CFRmax) of the left anterior descending arteryTime frame: Baseline, 6 months, and 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Qilu Hospital of Shandong University
Jinan, Shandong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.